^
    Back
    Association details:
    Biomarker:ERBB4 expression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Oncotarget
    Title:

    Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

    Excerpt:
    In addition, higher nuclear HER4 expression at day 21 was correlated with a poorer clinical response to trastuzumab monotherapy, including a higher tumour volume (r=0.859, p=0.023)...
    DOI:
    10.18632/oncotarget.1904